HC Wainwright Lifts Earnings Estimates for MiNK Therapeutics

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of MiNK Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn $0.24 per share for the year, up from their prior forecast of $0.16. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($0.33) per share.

Separately, Robert W. Baird cut their price objective on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday.

MiNK Therapeutics Stock Performance

NASDAQ:INKT opened at $0.75 on Monday. The stock has a 50-day simple moving average of $0.73 and a 200 day simple moving average of $0.85. MiNK Therapeutics has a 52-week low of $0.57 and a 52-week high of $1.90. The company has a market cap of $29.81 million, a PE ratio of -1.93 and a beta of 0.05.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC increased its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the period. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.